Developer docs
API playgroundTry for free, no card

Search company profiles

54gene

Full company profile

uuid0000c41

Namestring
54gene
Legal namestring
54gene
Websiteurl
54gene.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

54gene was a Nigerian health technology company founded in 2019 by Abasi Ene-Obong, focused on collecting, storing, and analyzing genetic data and biospecimens from African populations. The company addressed a documented gap in global genomic research, where African populations were historically underrepresented in genetic databases used for drug discovery and precision medicine. Its core offering centered on building a proprietary African genomic database through partnerships with healthcare and research institutions across the continent, with the intent to license this data and provide analysis services to pharmaceutical and biotech companies engaged in drug discovery and diagnostics development.

The company's go-to-market was direct enterprise sales targeting pharmaceutical companies, biotech firms, and research institutions, supported by participation in genomics industry conferences and scientific publications to build thought leadership. Its revenue model was data monetization — generating income through genomic data analysis services, biobanking functions, and licensing genetic data assets for pharmaceutical research. Customer segments were organized vertically: pharmaceutical and biotech companies seeking diverse genomic inputs for drug development, and healthcare and research institutions requiring African genomic data for disease diagnosis and treatment.

Despite raising over $45 million in total disclosed funding across seed (Y Combinator, 2019), Series A ($15M led by Adjuvant Capital, 2020), and Series B ($25M led by Cathay AfricInvest Innovation Fund, September 2021), 54gene collapsed after rapid COVID-era scaling and overextension. The company failed to convert post-seed momentum into sustainable revenue growth, and its founder subsequently transitioned to lead Syndicate Bio. The case is now cited as a cautionary example of African health-tech startups that achieved headline funding but could not reach commercial viability.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLagos, Nigeria
HQ citystring
Lagos
HQ countrystring
Nigeria
HQ regionstring
Africa
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
African genomics, genetic data services, drug discovery, biobanking services, precision medicine
Industry4 codes
PRIMARYHLAAANAL
Population Genomics & Preventive Precision Health Programs
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code3 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Genomic Data Services
Social media profiles3 records
Revenue model1 record
1Genomic Data Services
TypeData Monetisation
Description

Revenue generated through genomic data analysis services, biobanking functions, and potentially licensing genetic data for pharmaceutical research and drug discovery purposes

biospace.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

54gene was a health technology company that collected, stored, and analyzed genetic data and biospecimens from African populations to improve genomic diversity in research, diagnosis, and disease treatment. The company provided genomic data services, biobanking functions, and analytical capabilities to pharmaceutical, biotech, and research institutions for drug discovery and diagnostics development.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

54gene was a health technology company focused on African genomics, working to improve genomic diversity in research, diagnosis, and treatment of diseases. The company was involved in drug discovery, genomics, and diagnostics across Africa. However, specific named products or modules are not detailed in the available sources.

Product and service1 record
1African Genomic Data Collection and Analysis
CategoryGenomic Data Services
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Consumer and therapeutics genomics company that built a large proprietary genetic database and licenses data to pharmaceutical companies for drug discovery. Closely comparable to 54gene's genomic-data-plus-pharma-partnership model.

2Ancestry
TypeBroad incumbent
Description

Operates one of the world's largest consumer genomic databases with extensive ancestry-focused DNA collections and ancillary health services. Comparable as a large-scale genomic data operator, though skewed toward European-ancestry samples unlike 54gene's African focus.

TypeDirect peer
Description

Population genomics and DNA sequencing platform that partners with health systems and population-health programs to build large-scale genomic databases. Directly comparable business model to 54gene's biobank-plus-pharma approach.

TypeDirect peer
Description

Population genomics company offering genetic testing at scale and partnering with employers, health systems, and pharma on population health. Directly comparable genomics-as-a-service proposition with enterprise B2B channels similar to 54gene's pharma and research customers.

TypeBroad incumbent
Description

Iceland-based genomics pioneer now owned by Amgen that built a national-scale population biobank used for drug target discovery. Highly comparable as a population-genomics-for-drug-discovery business, though at greater scale and maturity.

TypeOthers
Description

Pharma-sponsored large-scale human sequencing effort linked to drug discovery at Regeneron. Comparable as a model where a biobank is tied directly into pharma pipelines, though embedded within a single sponsor rather than sold across the industry like 54gene.

TypeEmerging player
Description

Genomics and precision-health company combining large-scale sequencing with health-risk prediction and pharma partnerships. Comparable technology stack and go-to-market, though focused on wealthy individual customers rather than African populations.

TypeEmerging player
Description

Personal genomics platform that emphasizes privacy-preserving genomic data ownership and serves both consumers and researchers. Comparable data-monetization model where individuals contribute genetic data that is licensed for research.

9Genomics England
TypeRegional player
Description

UK government-backed initiative building a national genomic dataset from the NHS for research and clinical use. Comparable as a population-scale genomics platform; operates under a public mandate in a single country rather than across African markets.

TypeEmerging player
Description

African-focused genomics venture founded by 54gene's former founder, Abasi Ene-Obong, after 54gene's collapse. Most directly comparable as a continuation of the African genomic data thesis using the same domain expertise.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

54gene

Genomic Data Services54gene.com

What 54gene does

54gene was a Nigerian health technology company founded in 2019 by Abasi Ene-Obong, focused on collecting, storing, and analyzing genetic data and biospecimens from African populations. The company addressed a documented gap in global genomic research, where African populations were historically underrepresented in genetic databases used for drug discovery and precision medicine. Its core offering centered on building a proprietary African genomic database through partnerships with healthcare and research institutions across the continent, with the intent to license this data and provide analysis services to pharmaceutical and biotech companies engaged in drug discovery and diagnostics development.

The company's go-to-market was direct enterprise sales targeting pharmaceutical companies, biotech firms, and research institutions, supported by participation in genomics industry conferences and scientific publications to build thought leadership. Its revenue model was data monetization — generating income through genomic data analysis services, biobanking functions, and licensing genetic data assets for pharmaceutical research. Customer segments were organized vertically: pharmaceutical and biotech companies seeking diverse genomic inputs for drug development, and healthcare and research institutions requiring African genomic data for disease diagnosis and treatment.

Despite raising over $45 million in total disclosed funding across seed (Y Combinator, 2019), Series A ($15M led by Adjuvant Capital, 2020), and Series B ($25M led by Cathay AfricInvest Innovation Fund, September 2021), 54gene collapsed after rapid COVID-era scaling and overextension. The company failed to convert post-seed momentum into sustainable revenue growth, and its founder subsequently transitioned to lead Syndicate Bio. The case is now cited as a cautionary example of African health-tech startups that achieved headline funding but could not reach commercial viability.

54gene firmographics

Firmographics
Name
54gene
Legal name
54gene
Website
https://54gene.com
Company type
Private
Founded year
2019
Operating status
Closed
Headcount range
101–250 employees
Ownership category
akta.pro rank

54gene industry classification

Industry
Product category
Genomic Data Services
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAANAL
Population Genomics & Preventive Precision Health Programs
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • African genomics
  • Genetic data services
  • Drug discovery
  • Biobanking services
  • Precision medicine

Where 54gene is headquartered

Location

Headquarters

HQ city
Lagos
HQ country
Nigeria
HQ region
Africa

Offices1 record

Markets served

54gene business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Genomic Data Services: Revenue generated through genomic data analysis services, biobanking functions, and potentially licensing genetic data for pharmaceutical research and drug discovery purposes

Distribution channels1 record

Marketing channels2 records

54gene product offering

Product offering

Core offering

54gene was a health technology company that collected, stored, and analyzed genetic data and biospecimens from African populations to improve genomic diversity in research, diagnosis, and disease treatment. The company provided genomic data services, biobanking functions, and analytical capabilities to pharmaceutical, biotech, and research institutions for drug discovery and diagnostics development.

Product overview

54gene was a health technology company focused on African genomics, working to improve genomic diversity in research, diagnosis, and treatment of diseases. The company was involved in drug discovery, genomics, and diagnostics across Africa. However, specific named products or modules are not detailed in the available sources.

Differentiator

Problem solved

Functional benefit

Products and services

  • African Genomic Data Collection and Analysis

Companies that use 54gene

Customer profile

Segments2 records

Ideal customer profiles2 records

54gene technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

54gene partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves2 records

Expansion highlights4 records

54gene competitors and assessment

Company assessment

Direct peers

  • 23andMe: Consumer and therapeutics genomics company that built a large proprietary genetic database and licenses data to pharmaceutical companies for drug discovery. Closely comparable to 54gene's genomic-data-plus-pharma-partnership model.
  • Helix: Population genomics and DNA sequencing platform that partners with health systems and population-health programs to build large-scale genomic databases. Directly comparable business model to 54gene's biobank-plus-pharma approach.
  • Color Health: Population genomics company offering genetic testing at scale and partnering with employers, health systems, and pharma on population health. Directly comparable genomics-as-a-service proposition with enterprise B2B channels similar to 54gene's pharma and research customers.

Broad incumbents

  • Ancestry: Operates one of the world's largest consumer genomic databases with extensive ancestry-focused DNA collections and ancillary health services. Comparable as a large-scale genomic data operator, though skewed toward European-ancestry samples unlike 54gene's African focus.
  • deCODE genetics: Iceland-based genomics pioneer now owned by Amgen that built a national-scale population biobank used for drug target discovery. Highly comparable as a population-genomics-for-drug-discovery business, though at greater scale and maturity.

Others

  • Regeneron Genetics Center: Pharma-sponsored large-scale human sequencing effort linked to drug discovery at Regeneron. Comparable as a model where a biobank is tied directly into pharma pipelines, though embedded within a single sponsor rather than sold across the industry like 54gene.

Emerging players

  • Human Longevity Inc. Genomics and precision-health company combining large-scale sequencing with health-risk prediction and pharma partnerships. Comparable technology stack and go-to-market, though focused on wealthy individual customers rather than African populations.
  • Nebula Genomics: Personal genomics platform that emphasizes privacy-preserving genomic data ownership and serves both consumers and researchers. Comparable data-monetization model where individuals contribute genetic data that is licensed for research.
  • Syndicate Bio: African-focused genomics venture founded by 54gene's former founder, Abasi Ene-Obong, after 54gene's collapse. Most directly comparable as a continuation of the African genomic data thesis using the same domain expertise.

Regional players

  • Genomics England: UK government-backed initiative building a national genomic dataset from the NHS for research and clinical use. Comparable as a population-scale genomics platform; operates under a public mandate in a single country rather than across African markets.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

54gene social profiles

Digital presence

54gene financial estimates

Financial estimate

Revenue estimate

Valuation estimate

54gene leadership team

Management profile

Number of profiles

54gene funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

54gene M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 54gene

What does 54gene do?

54gene was a health technology company that collected, stored, and analyzed genetic data and biospecimens from African populations to improve genomic diversity in research, diagnosis, and disease treatment. The company provided genomic data services, biobanking functions, and analytical capabilities to pharmaceutical, biotech, and research institutions for drug discovery and diagnostics development.

Is 54gene a public or private company?

54gene is a private company. It is classified as venture growth investor backed and is currently closed.

When was 54gene founded?

54gene was founded in 2019. It employs 101 to 250 people.

Where is 54gene based?

54gene is headquartered in Lagos, Nigeria, in the Africa region.

How does 54gene make money?

One revenue line is on record: genomic Data Services.

Who are 54gene's main competitors?

Direct peers on record are 23andMe, Helix and Color Health. Broad incumbents are Ancestry and deCODE genetics. Regeneron Genetics Center is listed as an others. Emerging players are Human Longevity Inc., Nebula Genomics and Syndicate Bio. Genomics England is listed as a regional player.

Does 54gene have an API?

No public API is recorded for 54gene.

What industry is 54gene in?

54gene's product category is Genomic Data Services. Its primary akta.pro industry code is HLAAANAL, Population Genomics & Preventive Precision Health Programs, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FrontiersWhen genomics companies act as biobanks: governance challenges in an era of genomic assetizationThis academic paper examines how genomics companies increasingly perform biobanking functions—collecting, storing, and sharing genetic data and biospecimens—without being formally recognized or governed as biobanks, creating governance gaps around data stewardship during organizational change. Using comparative case studies of 54gene (a Nigerian genomics company), 23andMe (whose data holdings became central during bankruptcy proceedings), and DNA marketplace models, the paper identifies structural vulnerabilities arising from venture capital financing, assetization of genomic data, and cross-border investment in the sector. The findings highlight the need for ecosystem-level governance approaches including clearer asset-transfer rules, default public stewardship safeguards during insolvency, and shared continuity-planning standards across public, nonprofit, and commercial biobanks.TechCabalFive African founders who staged major comebacks in 2025African tech venture funding has recovered to over $3 billion in 2025, a 36% jump from $2.2 billion, with capital now flowing in larger, more deliberate tranches focused on proven business models rather than early-stage experiments. The article profiles five African founders who returned after startup failures—Meshack Alloys (Sendy to TABB), Tesh Mbaabu (MarketForce to Cloud9), Abasi Ene-Obong (54gene to Syndicate Bio), William McCarren (Zumi to FARO), and Alexandria Procter (DigsConnect to Pharos of Alexandria Ventures)—illustrating how failure is being reframed as a stress test that provides granular market knowledge. This shift reflects a broader trend where investors prioritize operational discipline, capital efficiency, and revenue-generating businesses over speculative expansion, with local banks increasingly participating through structured debt.National Center for Biotechnology InformationBeyond seed funding: why Nigerian digital health startups struggle to growA narrative review of Nigerian digital health startups from 2019 to 2025 reveals that despite a surge in seed funding peaking at $1.8 billion for Nigerian tech in 2021, few health-tech ventures successfully convert to Series A or B funding, with only about 6 of 54 funded startups reaching Series A and 5 progressing to Series B. The analysis identifies post-seed conversion barriers including regulatory ambiguity, infrastructure gaps, market trust deficits, talent shortages, and the proof-to-procurement (P2P) gap where ventures prove their concept but lack pathways for widespread adoption by payers. Case narratives of Helium Health (which achieved pan-African expansion and a $30M Series B), 54gene (which collapsed after rapid scaling amid COVID-era overextension), and Reliance Health (which pivoted from telemedicine to integrated insurance) illustrate how strategic adaptability, revenue model viability, and external environment alignment determine post-seed trajectories.TechCabalAfrica’s Startup Ice Age: Why Leaner Could Mean StrongerAfrica's venture capital market slowed in 2024, with startups raising $393 million in H1, a 57% drop from H1 2023. Shutdowns of 54gene and Sendy exposed unsustainable growth models, while BuuPass and Logidoo found strength in revenue-generating B2B tools. Investors expect consolidation in 2025 as capital efficiency becomes a competitive advantage.NairametricsAfter raising over $70 million these Nigerian startups shut down in 2023Nine Nigerian startups that collectively raised over $70 million in the past two years shut down in 2023, including Pivo, Lazerpay, and 54gene. Venture capitalists argue the failures stem from rushed funding and insufficient due diligence, urging founders to meet higher viability standards.Yahoo54gene valuation slashed by over $100M amid job cuts and CEO exitAfrican genomics startup 54gene has slashed its valuation by over $100 million to approximately $50 million amid a second round of layoffs affecting more than 100 employees and the resignation of CEO Dr. Abasi Ene-Obong. The company secured fresh capital through a bridge round with aggressive liquidation preferences, coinciding with internal disputes and allegations of financial mismanagement that contributed to executive departures. This downturn marks a significant contraction for the Y Combinator-backed biotech, which had previously raised substantial funding during the pandemic but now faces severe operational and financial challenges.WeeTrackerThe Demise Of 54gene: Insiders Trace How Boom Turned Bust54gene, an African biotech firm, has shut down, with founder Dr Abasi Ene-Obong leaving in October 2022. Insiders cite lawsuits, fraud allegations, and a misalignment over capital-intensive diagnostics diversification. The company had raised over $45M and amassed 200,000 samples.TechCabalExclusive: After raising $45m in two years, 54gene is shutting down54gene, a genomics startup, is shutting down after raising $45 million in three rounds. The company, which aimed to provide African genomic data, has been winding down since July 2023, with legal disputes and unpaid creditors complicating the closure. It is seeking buyers for its assets, including a biobank.TechnextGenomics startup, 54gene, initiates shutdown after raising $45 million54Gene, a genomics startup, has begun winding down operations after raising $45 million across three funding rounds. The company, founded in 2019 to provide African genomic data, faced financial challenges and legal disputes, including a lawsuit from former legal counsel Teresia Bost. It is seeking buyers for its assets, including a biobank, though the sale process remains uncertain.